Medtronic plc (MDT)
Health Care · Health Care Equipment · US stock · S&P 500 component
$94.75
▼ -0.70 (0.73%)
Fair valueFair
$78 −17.6% to fair value
$39fair band $55–$101$117
Day's range
$94.26 – $96.50
52-week range
$72.06 – $102.92
About Medtronic plc
Medtronic is a medical technology company that makes devices and therapies for chronic conditions. Its products include heart rhythm devices, heart valves, spinal and brain implants, surgical tools, insulin pumps and glucose monitors. Revenue comes from selling these devices and related supplies to hospitals, clinics and patients around the world. The business depends on clinical evidence, regulatory approvals and relationships with physicians and health systems.
Revenue over the last twelve months came to $37.5 billion. The three-year revenue growth rate is 5.2% a year. Profitability shows an operating margin of 18.1% and a return on invested capital of 8%. Net debt stands at 2.0 times EBITDA. Shareholders receive a dividend, yielding 3.0%. This gives an X-Ray Score of 56 out of 100. These figures describe past results as reported and are a factual snapshot, not a forecast. Some measures, such as margins for real estate trusts and banks, are defined differently from those of industrial firms, so comparisons should be made with care.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $72.06 – $102.92Volume 30,274,700Daily, split-adjusted
Vitals
Market cap$121.8B
52-week range$72.06 – $102.92
Volume (last day)30,274,700
P/E (TTM)283.7
EBIT / EV yield4.8%
Free-cash-flow yield5.0%
Dividend yield3.0%
Revenue (TTM)$37.5B
Net income (TTM)$430M
Operating margin18.1%
Return on capital7.8%
Debt incl. leases$28.2B
Cash & securities$8.8B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$78model spread $74 – $81
Fair
−17.6% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $95
Undervalued < $55Fair $55 – $101Overvalued > $101
10-year DCF (market-scaled)
$71
Peer multiples
$104
Earnings power floor (not blended)
$32
Fundamentals-adjusted multiple
$59
Growth the price implies
14.6%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Average business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Fair
52/100
Priced about in line with its sector.
See the numbers →
EBIT / EV yield4.8%
Free-cash-flow yield5.0%
Fair value vs price0.8×
Growth
Fair
58/100
Growing at a typical pace for its sector.
See the numbers →
Revenue growth (3y)5.2%
EPS growth (3y)9.8%
Growth consistency100%
Profitability
Fair
56/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital7.8%
Operating margin18.1%
Gross profitability26.2%
Financial health
Fair
64/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score8 / 9
Net debt / EBITDA2.0×
Interest cover9.4×
Dividends
Weak
35/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield3.0%
Dividends vs free cash flow60%
Dividend growth0.2%
Quarterly results: last 6 quarters
+3.9%
Apr '25
+8.4%
Jul '25
+6.6%
Oct '25
+8.7%
Jan '26
+9.9%
Apr '26
+13.7%
Jul '26
Revenue against the same quarter a year earlier. Latest quarter revenue $9.8B, diluted EPS $1.14.
Compare with peers
RMD Resmed Inc73 DXCM Dexcom Inc71 PODD Insulet Corp69 IDXX Idexx Laboratories Inc67Other Health Care Equipment companies by X-Ray Score.
Fundamentals checklist
● 4 Good · ● 11 Average · ● 1 BadCash quality
Earnings backed by cashGood
Free-cash-flow yieldAverage
Risk models
Altman Z''Average
Piotroski F-ScoreGood
Growth
EPS growth (3y)Average
Free-cash-flow growth (3y)Average
Revenue growth (3y)Average
Growth consistencyGood
Balance sheet
Current ratioGood
Net debt / EBITDAAverage
Interest coverAverage
Valuation
Fair value vs priceAverage
EBIT / EV yieldAverage
Profitability
Return on invested capitalBad
Operating marginAverage
Gross profitabilityAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 56/100.
Financials
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Revenue | $31.7B | $31.2B | $32.4B | $33.5B | $36.4B |
| Operating income | $5.8B | $5.5B | $5.1B | $6.0B | $6.5B |
| Net income | $5,039 | $3,758 | $3,676 | $4,662 | $4,801 |
| Operating cash flow | $7.3B | $6.0B | $6.8B | $7.0B | $7.3B |
| Operating margin | 18.2% | 17.6% | 15.9% | 17.8% | 17.8% |
| Free cash flow | $6.0B | $4.6B | $5.2B | $5.2B | $5.4B |
| Diluted EPS | $3.73 | $2.82 | $2.76 | $3.61 | $3.73 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 1 neutral · 3 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 90.62 | Bullish |
| EMA 10 | 91.79 | Bullish |
| SMA 20 | 89.40 | Bullish |
| EMA 20 | 90.61 | Bullish |
| SMA 50 | 90.38 | Bullish |
| EMA 50 | 89.21 | Bullish |
| SMA 100 | 85.44 | Bullish |
| EMA 100 | 87.57 | Bullish |
| SMA 200 | 86.94 | Bullish |
| EMA 200 | 87.01 | Bullish |
Oscillators (daily)
| RSI (14) | 64.64 | Neutral |
| MACD (12, 26) | 1.08 | Bullish |
| Momentum (12) | 9.80 | Bullish |
| Stochastic %K (14) | 84.49 | Bearish |
| Williams %R (14) | -15.51 | Bearish |
| CCI (20) | 160.1 | Bearish |
Pivot points (classic, last session)
S3 91.60 | S2 92.93 | S1 93.84 | Pivot 95.17 | R1 96.08 | R2 97.41 | R3 98.32 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
2.86 USD
Yield on today's price
3.02%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 25 Sep 2026 | 0.7200 |
| 26 Jun 2026 | 0.7200 |
| 27 Mar 2026 | 0.7100 |
| 26 Dec 2025 | 0.7100 |
| 26 Sep 2025 | 0.7100 |
| 27 Jun 2025 | 0.7100 |
| 28 Mar 2025 | 0.7000 |
| 27 Dec 2024 | 0.7000 |
| 27 Sep 2024 | 0.7000 |
| 28 Jun 2024 | 0.7000 |
| 21 Mar 2024 | 0.6900 |
| 19 Dec 2023 | 0.6900 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
MDT SEC filings
17 Sep 2026
8-KSEC EDGAR
Other events
3 Sep 2026
10-QSEC EDGAR
Quarterly report
1 Sep 2026
8-KSEC EDGAR
Results of operations
17 Aug 2026
DEF 14ASEC EDGAR
Proxy statement
18 Jun 2026
10-KSEC EDGAR
Annual report
3 Jun 2026
8-KSEC EDGAR
Results of operations
18 May 2026
8-KSEC EDGAR
Director or officer change
27 Apr 2026
8-KSEC EDGAR
Regulation FD disclosure
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.